CML, chronic myeloid leukemia
Conditions
Interventions
The use of a TPO-R agonist. This is retrospective research, so the use and dosage will vary from patient to patient.
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Inclusion criteria
Inclusion criteria: Patients are selected based on the requirement: CML under treatment (or previously treated) with a TPO agonist as a result of pancytopenia. These are competent, adult patients who have given informed consent.
Exclusion criteria
Exclusion criteria: Disease other than CML, under 18 years of age, no treatment with TKI, no pancytopenia, no TPO agonist used.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameters will, first, be the haematological response to TPO-R agonists focussing on changes in blood cell counts and its timing and degree. Other parameters will be the mean treatment time required to achieve haematological recovery and whether the use of TPO-R agonists allow for continuation of TKI-treatment at full or reduced dosage. | — |
Secondary
| Measure | Time frame |
|---|---|
| N.A. | — |
Countries
Netherlands
Contacts
Public ContactWEP Groenewoud
Radboud Universitair Medisch Centrum
Outcome results
None listed